Axial Therapeutics competitors

Howard Doong is a Chief Executive Officer at American BriVision Holding Corp and Chairman and CEO at LifeCode Biotechnology Company and is based in 台北, Taipei City Special Municipality, Taiwan. He has worked as Chief Technology Officer at Lih Pao Life Science, Vice President and Director of Quality Assurance at TrimGen Corporation, and Chief Scientific Officer at Cold Spring Biotech Corp.. Howard works or has worked as BOARD MEMBER at LihPao Laboratory of Cancer Genomic Medicine. He studied at University of Chicago, NACUBO Market Value of Univ of New Hampshire Endowment Assets, and Massachusetts Institute of Technology.

Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Stephen Collins is a Board Member at SPINIFEX PHARMACEUTICALS PTY, Board Member at NeuroTherapeutics Pharma Inc, and President/CEO at NeuroTherapeutics Pharma Inc. He has worked as Global Senior Director at Johnson & Johnson. Stephen works or has worked at Abbott and CASE WESTERN RESERVE UNIVERSITY and works or has worked as Professor at UC Davis and Chief Executive Officer at NTP Nano Tech Projects srl. He attended CASE WESTERN RESERVE UNIVERSITY and UC Davis.

David has significant “hands on” experience in pharma/biotech with proficiency in the following areas:* Strategic, creative leader with Executive and BOD experience in start-ups to established companies both public and private with over $100M in capital raised* M&A: Led cross functional R&D and Commercial teams in the evaluation of the entire product portfolio leading to the acquisition of Serono Biotech for $13.5B. Honored by Merck Board as a top contributor in closing the deal* M&A: Leader of cross-functional teams including Discovery, Clinical Development, Regulatory, IP and Commercial in the evaluation of over 40 companies ranging in value from $200M-$18B* Licensing: Leader of scientific and business cross-functional team assessment of over 700 cancer targets leading to 40 due diligences and two signed term sheets* Deep understanding of drug development, Regulatory, all Commercial/business functions, IP, Manufacturing and Operations* Global experience in launch preparation of orphan drugs to billion-dollar brands* Expertise at both the strategic and operational level and most enjoy building new businesses from the ground up*P&L responsibility